Drug pipeline: 1Q17

The first quarter saw a rash of approvals. Among the most noteworthy small molecules are the first new drug for Parkinson’s disease…

Para acessar a publicação na íntegra clique  aqui

Fonte: 400 VOLUME 35 NUMBER 5 MAY 2017 NATURE BIOTECHNOLOGY